| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/11/2012 | EP2437758A1 Bacteria thya(-) mutants with increased vitamin k |
| 04/11/2012 | EP2437756A2 Pure peg-lipid conjugates |
| 04/11/2012 | EP2437755A1 Surface active agent compositions and methods for enhancing oxygenation, reducing bacteria and improving wound healing |
| 04/11/2012 | EP2437754A1 Lipopolysaccharide of ochrobactrum intermedium and their use as immunostimulant of mammalians |
| 04/11/2012 | EP2437753A1 Synthetic glucopyranosyl lipid adjuvants |
| 04/11/2012 | EP2437752A2 Peptide dicer substrate agents and methods for their specific inhibition of gene expression |
| 04/11/2012 | EP2437751A2 Peptide dicer substrate agents and methods for their specific inhibition of gene expression |
| 04/11/2012 | EP2437750A1 Identification of micro-rnas involved in post-myocardial infarction remodeling and heart failure |
| 04/11/2012 | EP2437749A2 Interlaced method for treating cancer or a precancerous condition |
| 04/11/2012 | EP2437748A1 Combination preparations comprising a cytokine antagonist and corticosteroid |
| 04/11/2012 | EP2437747A1 Combination preparations comprising exosomes and corticosteroid |
| 04/11/2012 | EP2437746A2 17 beta-alkyl-17 alpha-oxy-estratrienes |
| 04/11/2012 | EP2437745A1 Treatment of mammalian disorders mediated by alpha-carbonic anhydrase isoforms |
| 04/11/2012 | EP2437744A2 Modulation of kcnq potassium channel activity for treatment of psychiatric disorders and the symptoms thereof |
| 04/11/2012 | EP2437743A1 Ophthalmic formulations of fluticasone and methods of use |
| 04/11/2012 | EP2437742A1 New compositions for treating cmt and related disorders |
| 04/11/2012 | EP2437741A1 The use of amlexanox in the therapy of neutrophil-driven diseases |
| 04/11/2012 | EP2437740A1 Treatment of tinnitus and associated auditory dysfunctions |
| 04/11/2012 | EP2437739A1 Glomerulonephritis treatment |
| 04/11/2012 | EP2437738A2 Methods and compositions for the treatment of cancer |
| 04/11/2012 | EP2437737A1 Composition including at least one trans-cinnamaldehyde and the use thereof in the treatment of bacterial infections, specifically in the treatment of nosocomial infections |
| 04/11/2012 | EP2437733A1 Sustained release dosage form |
| 04/11/2012 | EP2437732A1 Combination of dopamine agonists plus first phase insulin secretagouges for the treatment of metabolic disorders |
| 04/11/2012 | EP2437729A2 Tamper resistant dosage form comprising a matrix and melt-extruded particulates comprising a drug |
| 04/11/2012 | EP2437725A1 Topical micro-emulsions for the treatment of rheumatic disorders |
| 04/11/2012 | EP2437722A1 Ophthalmic oil-in-water emulsions containing cyclosporine or a polyphenol |
| 04/11/2012 | EP2437719A1 Treatment of eye discomfort by topical administration of a cooling agent to the external surface of the eyelid |
| 04/11/2012 | EP2437617A2 Ginger compositions |
| 04/11/2012 | EP2437606A1 Compositions and methods for increasing telomerase activity |
| 04/11/2012 | EP2437603A1 Methods of treating hepatic encephalopathy |
| 04/11/2012 | EP2437600A1 Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists |
| 04/11/2012 | EP2437596A1 Skin treatment compositions |
| 04/11/2012 | EP2310383B8 Derivatives of 2-oxo-alkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same |
| 04/11/2012 | EP2188253B8 Indol-2-one derivatives disubstituted in 3-position, preparation thereof and therapeutic use thereof |
| 04/11/2012 | EP2143435B1 Method for extracting secoisolariciresinol and dihydroquercetin from wood |
| 04/11/2012 | EP2131845B1 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide mesylate, hydrates and polymorphs thereof, and formulations comprising these forms |
| 04/11/2012 | EP2119718B1 Macrocyclic compound |
| 04/11/2012 | EP2094662B1 Polycyclic acid compounds useful as crth2 antagonists and antiallergic agents |
| 04/11/2012 | EP2068880B1 Method for treating cancer harboring egfr mutations |
| 04/11/2012 | EP2068838B1 Pharmaceutical formulations comprising clopidogrel |
| 04/11/2012 | EP2068812B1 Medicinal package |
| 04/11/2012 | EP2062883B1 Catechin as insulin sensitivity improving agent |
| 04/11/2012 | EP2059508B1 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin ii receptor antagonists |
| 04/11/2012 | EP2054390B1 Indazole derivatives that inhibit trpv1 and uses thereof |
| 04/11/2012 | EP2018153B1 Liquid oral compositions |
| 04/11/2012 | EP2012780B1 Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors |
| 04/11/2012 | EP1991248B1 Antidepressant prodrugs |
| 04/11/2012 | EP1986631B1 Methoxypolyethylene glycol thioester chelate and uses thereof |
| 04/11/2012 | EP1970075B1 THERAPEUTIC AGENT FOR NEUROBLASTOMA TARGETING ARID3b |
| 04/11/2012 | EP1963319B1 Heteroarylpyrrolopyridinones active as kinase inhibitors |
| 04/11/2012 | EP1957082B1 Use of high-dose oxazaphosphorine drugs for treating immune disorders |
| 04/11/2012 | EP1948667B1 Thiazolo[4,5-c]pyridine derivatives as mglu5 receptor antagonists |
| 04/11/2012 | EP1910838B1 Uses of cancer specific glycans |
| 04/11/2012 | EP1902031B1 Cathepsin cysteine protease inhibitors |
| 04/11/2012 | EP1902030B1 Substituted quinolones ii |
| 04/11/2012 | EP1876893B1 Cancer treatment by combined inhibition of proteasome and telomerase activities |
| 04/11/2012 | EP1858490B1 Pharmaceutical forms with improved pharmacokinetic properties |
| 04/11/2012 | EP1851205B1 Pyridazine derivatives and their use as therapeutic agents |
| 04/11/2012 | EP1794120B1 Peptidase inhibitors |
| 04/11/2012 | EP1781612B1 Shortened method for the production of l-lobeline |
| 04/11/2012 | EP1753729B1 Novel imidazole derivatives, the production thereof, and the use of the same as intermediate products for producing medicaments and pesticides |
| 04/11/2012 | EP1724258B1 Heteroarylphenylurea derivative |
| 04/11/2012 | EP1683526B1 Aqueous solution preparation containing aminoglycoside antibiotic and bromfenac |
| 04/11/2012 | EP1675552B1 Preperation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors |
| 04/11/2012 | EP1673356B1 Substituted benzylaminoalkylene heterocycles |
| 04/11/2012 | EP1654375B1 Process for the production of biologically active oils |
| 04/11/2012 | EP1652842B1 Indazole derivatives |
| 04/11/2012 | EP1651612B1 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| 04/11/2012 | EP1650191B1 Therapeutic agent for chronic obstructive pulmonary disease and method of treatment for chronic obstructive pulmonary disease with the same |
| 04/11/2012 | EP1589958B2 Reduced dose of tolterodine for treating urinary disorders |
| 04/11/2012 | EP1560566B1 Controlled and continued delivery of rifaximin |
| 04/11/2012 | EP1532153B8 Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| 04/11/2012 | EP1492531B3 Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillin |
| 04/11/2012 | EP1463528B1 Selective norepinephrine serotonin reuptake inhibitors for treating fibromyalgia syndrome, chronic fatique syndrome and pain |
| 04/11/2012 | EP1377596B1 Ttk in diagnosis and as a therapeutic target in cancer |
| 04/11/2012 | EP1362030B1 Novel benzoylguanidine salt |
| 04/11/2012 | EP1326840B1 Substituted heterocyclic compounds for treating multidrug resistance |
| 04/11/2012 | EP1296923B3 Aspirin-triggered lipid mediators |
| 04/11/2012 | EP1261590B1 Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases |
| 04/11/2012 | EP1194123B1 Method for controlled production of ultrafine microparticles and nanoparticles |
| 04/11/2012 | EP1125947B1 Human H37 protein and cDNA encoding the same |
| 04/11/2012 | DE202011002370U1 Stoffgemisch und Infusion- oder Trinklösung Mixture and Infusion or oral solution |
| 04/11/2012 | CN1960729B 伊立替康制剂 Irinotecan preparations |
| 04/11/2012 | CN1935138B 用于持续,不变且独立释放活性化合物的基质 For a sustained, invariant and independent release of the active compound matrix |
| 04/11/2012 | CN1900077B New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
| 04/11/2012 | CN1856300B Neutral amino acid replenishers for treating conditions associated with metabolic disorders |
| 04/11/2012 | CN102414318A Jarid1b for target gene of cancer therapy and diagnosis |
| 04/11/2012 | CN102414291A Process for producing 1-menthyl (3s)-3-hydroxybutanoate and composition for stimulating sense |
| 04/11/2012 | CN102414290A (3r)-3-羟基丁酸l-薄荷酯、其制备方法、以及包含它的感觉刺激组合物 (3r) -3- hydroxybutyrate l- menthyl, its preparation, and its sensory stimulation comprising compositions |
| 04/11/2012 | CN102414216A 1-(2'-氰基-2'-脱氧-β-D-阿拉伯呋喃糖基)胞嘧啶一盐酸盐的新型稳定型结晶 1- (2'-cyano-2'-deoxy--β-D- arabinofuranosyl) cytosine, a novel stable crystalline hydrochloride |
| 04/11/2012 | CN102414212A 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 And cyclopropyl-fused indole and inhibitors benzazepine * hcv ns5b |
| 04/11/2012 | CN102414211A 3-([1,2,3]三唑-4-基)吡咯并[2,3-b]吡啶衍生物 3 - ([1,2,3] triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives |
| 04/11/2012 | CN102414210A 作为β-分泌酶抑制剂的取代的咪唑并[1，2-a]吡啶衍生物、药物组合物和使用方法 -secretase Inhibitors as β- substituted imidazo [1,2-a] pyridine derivatives, pharmaceutical compositions and methods of use |
| 04/11/2012 | CN102414209A 运动障碍治疗剂 Dyskinesia therapeutic agent |
| 04/11/2012 | CN102414208A 作为用于认知性障碍的治疗中的gabaa受体逆激动剂的异*唑-噻唑衍生物 As a treatment for cognitive disorders in gabaa receptor inverse agonist iso * azole - thiazole derivatives |
| 04/11/2012 | CN102414207A Fluorinated aminotriazole derivatives |
| 04/11/2012 | CN102414206A Isoxazole-pyridine derivatives |
| 04/11/2012 | CN102414205A Isoxazole-pyrazole derivatives |
| 04/11/2012 | CN102414203A Isoxazole-pyridine derivatives as gaba modulators |
| 04/11/2012 | CN102414201A Novel solvate crystals |